SCI 발표논문

SCI 발표논문

← SCI 발표논문 목록

Gastric Cancer. 2025;28(5):749-759.

Positive association between anti-Helicobacter pylori IgG antibody titers and atrophic gastritis in a Latvian cohort.

, , , , , ,

제1저자 임주현 · 교신저자 박진영

소속 (7)
  1. Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
  2. Department of Internal Medicine, Healthcare Research Institute, Healthcare System Gangnam Center, Seoul National University Hospital, Seoul, South Korea.
  3. Early Detection, Prevention and Infections Branch, International Agency for Research On Cancer (IARC/WHO), 25 Avenue Tony Garnier, 69007, Lyon, France.
  4. Faculty of Medicine and Lifesciences, Institute of Clinical and Preventive Medicine, University of Latvia, Riga, Latvia.
  5. Digestive Diseases Centre GASTRO, Riga, Latvia.
  6. Academic Histology Laboratory, Riga, Latvia.
  7. Early Detection, Prevention and Infections Branch, International Agency for Research On Cancer (IARC/WHO), 25 Avenue Tony Garnier, 69007, Lyon, France. parkjy@iarc.who.int.

Abstract

BACKGROUND Although H. pylori is the most important risk factor for gastric cancer, the role of anti-H. pylori antibody titers in gastric carcinogenesis has not been investigated outside Asia. We aimed to analyze the relationship between H. pylori antibody titers and the risk of gastric precancerous lesions in a Caucasian population.

METHODS We analyzed the GISTAR pilot study data on participants from Latvia with available anti-H. pylori IgG antibody serology and histopathological information. Participants were classified into four groups according to antibody titer: low-negative (LN), high-negative (HN), low-positive (LP), and high-positive (HP). Odds ratios (ORs) for atrophic gastritis among the 4 groups were compared using logistic regression.

RESULTS Among a total of 1725 individuals, 970 with available histopathological information were included. A total of 738 individuals (76.1%) had histologically diagnosed atrophic gastritis. Risk of histological atrophic gastritis for each group compared to LN was as follows: HN (OR, 1.52; 95% confidence interval (CI) 0.85-2.72), LP (OR 2.04; 95% CI 1.25-3.32), and HP (OR, 2.47; 95% CI 1.50-4.07). Antibody titer as a continuous variable showed a positive relationship with histological atrophic gastritis (OR 1.09 per 10 EIU; 95% CI 1.04-1.14). The positive relationship was clearer among those aged ≥ 50 years.

CONCLUSIONS Anti-H. pylori antibody titer was positively related to the risk of atrophic gastritis in a middle-aged Caucasian population, suggesting its potential complementary role in gastric cancer risk stratification in a European setting where upper endoscopic examination is less routinely available.

© 2025. The Author(s) under exclusive licence to The International Gastric Cancer Association and The Japanese Gastric Cancer Association.

Keywords

Anti-Helicobacter pylori antibodyAtrophic gastritisGastric cancer

Conflict of interest statement

Declarations. Conflict of interest: The authors declare that they have no conflict of interest. Informed consent: Informed consent was obtained from all participants. Human rights statement: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1996 and later versions.

그 밖의 정보
출판 형태
Journal Article, Research Support, Non-U.S. Gov't
저널
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · eISSN 1436-3305
전자 출판
2025-06-16
MeSH
Humans · Gastritis, Atrophic* / microbiology / immunology / epidemiology / pathology / blood · Male · Female · Middle Aged · Helicobacter pylori* / immunology · Helicobacter Infections* / immunology / complications / microbiology · Latvia / epidemiology · Immunoglobulin G* / blood / immunology · Antibodies, Bacterial* / blood / immunology · Stomach Neoplasms* / microbiology / immunology / pathology · Aged · Pilot Projects · Adult · Risk Factors · Cohort Studies · Precancerous Conditions* / microbiology / immunology
Substances
Immunoglobulin G · Antibodies, Bacterial
연구비
World Health Organization 001
참고문헌
29편